The MRF is delighted to learn that Zelboraf (vemurafenib) has been approved in the European Union for the treatment of adult patients with BRAF V600 mutation-positive metastatic melanoma, the most dangerous form of skin cancer. Tests have shown that Zelboraf can extend the life expectancy in some patients with advanced melanoma who have the BRAF V600 mutation. Zelboraf is designed to target and inhibit mutated forms of the BRAF protein found in about half of all cases of melanoma.
Read more here: http://www.medicalnewstoday.com/articles/241937.php
To read the press release by the manufacturer of Zelboraf, please visit: http://www.roche.com/media/media_releases/med-cor-2012-02-20.htm